BamSEC and AlphaSense Join Forces
Learn More

Gain Therapeutics Inc. – Material Contracts

NASDAQ: GANX    
Share price (8/17/26): $2.04    
Market cap (8/17/26): $89.0 million

Material Contracts Filter

EX-10.18
from 10-K 3 pages Employment Contract Between Gt Gain Therapeutics SA via Francesco Soave 6, Ch-6900 Lugano, Switzerland (Hereinafter “Employer”) and Gianluca Fuqqetta [ ], Italian Citizen (Hereinafter “Employee”) Each of Them Hereinafter a “Party” and Together the “Parties”. the Parties Enter Into the Following Employment Contract (“Contract”): 1. Start Date: This Contract Shall Enter Into Force on January 1, 2025. July 1, 2022, Shall Remain the Start Date to Calculate the Employee’s Seniority With the Employer. 2. Duration: Undetermined 3. Level of Employment: 100%
12/34/56
EX-10.1
from 8-K 15 pages First Amended and Restated Employment Agreement
12/34/56
EX-10.2
from 10-Q 8 pages ​ June 27, 2024 ​ Matthias Alder ​ Re: Separation and General Release Agreement ​ Dear Matthias: ​
12/34/56
EX-10.1
from 8-K 25 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 33 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 10-Q 13 pages Indemnification Agreement
12/34/56
EX-10.3
from 10-Q 13 pages Indemnification Agreement
12/34/56
EX-10.1
from 8-K 5 pages Separation Agreement and Release
12/34/56
EX-10.1
from 8-K 15 pages Employment Agreement
12/34/56
EX-10.3
from 8-K 15 pages Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 19 pages September 19, 2022 Eric I. Richman C/O Gain Therapeutics, Inc. 4800 Montgomery Lane Suite 220 Bethesda, MD 20814 Re: Transition Agreement Dear Eric: This Letter Sets Forth the Substance of the Transition Agreement (The “Agreement”) Which Gain Therapeutics Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition
12/34/56
EX-10.8
from 10-K 18 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 9 pages Gain Therapeutics Inc. 2021 Inducement Equity Incentive Plan Non-Qualified Stock Option Award Agreement
12/34/56
EX-10.1
from 8-K 15 pages ​ Gain Therapeutics Inc. 2021 Inducement Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 18 pages Employment Agreement
12/34/56
EX-10.2
from S-1/A 10 pages Form of Indemnification Agreement
12/34/56
EX-10.1
from S-1/A 22 pages Gain Therapeutics Inc. 2020 Omnibus Incentive Plan
12/34/56
EX-10.11
from S-1 16 pages Common Stock Purchase Warrant Gain Therapeutics, Inc
12/34/56
EX-10.10
from S-1 13 pages Exchange Agreement
12/34/56
EX-10.8
from S-1 8 pages Lugano, November 2, 2020 Re: Your Employment at Gt Gain Therapeutics SA, Lugano: Dear Mr. Calabrese: In Accordance With Our Previous Understandings, We Wish to Confirm That It Is the Intention of Gt Gain Therapeutics SA, (Hereinafter the “Company”) to Enter Into This Indefinite Term Employment Agreement Upon the Terms and Conditions Hereinafter Specified. 1. Duties – Place of Work 1.1 You Will Be Employed by the Company as Executive, Effective From November 2nd, 2020, to Perform the Duties of “Chief Financial Officer” of the Company on a Full Time Basis and Reporting Ultimately to the Chief Executive Officer of Gain Therapeutics Inc (Hereinafter the “Parent Company”)
12/34/56